Open Access
Check for updates
International Journal of Medical Science and Dental Health (ISSN: 2454-4191)
Volume 11, Issue 08, August 2025,
Doi: https://doi.org/10.55640/ijmsdh-11-08-27

Viral Immune Evasion Strategies and Their Impact on Antiviral Therapy and Vaccine Development: A Review

Nadia Habeeb Sarhan
Department of Basic Science, Faculty of Nursing, University of Kufa, Iraq

Shahlaa Kh. Chabuk
Physiology Department, Hammurabi Medical College, University of Babylon, Babylon, Iraq

Ali Nurii Mardan
Najaf Ashraf Health Department, Incoming Examinations Center, Iraq

Afrah Hadib Dahi
Faculty of Pharmacy, University of Kufa, Iraq

Ali A. Al-fahham
Faculty of nursing, University of Kufa, Iraq

Corresponding Author - Ali A. Al-fahham

Received: 08 August 2025, **accepted:** 16 August 2025, **Published Date:** 31 August 2025

Abstract

Viral immune evasion, pathogenesis, strategy and mechanisms amidst host defenses has been genetically labeled the ability of viruses to develop multiple strategies against host defenses for their survival persistence, replication inside the same infected cell and later on, transmission. This involves inhibition of interferon signaling as well as MHC antigen presentation up to immune checkpoint modulation leading to immune exhaustion. Therefore, it has made a major contribution towards viral pathogenesis and an enormous drawback in antiviral therapeutic intervention or prophylactic vaccine development so far. However, recent advances in molecular virology and immunology that reveal the most subtle host-virus interactions occurring within this framework have the potential to overcome the limitations of current therapeutic approaches. These advances will be achieved through a deeper understanding of these interactions, the further development of advanced tools such as immune surveillance agents and checkpoint inhibitors, and the development of more precise vaccines. This review summarizes recent advances in viral immune evasion mechanisms and explores their potential impact on the development of antiviral therapies and vaccines. To emphasize the importance of a deeper understanding of viral pathogenesis for the rational development of new therapeutic and preventive interventions, we combine basic insights with clinical applications.

Keywords: Viral immune evasion, antiviral therapy, vaccine design

Introduction

Viruses are pathogens. They are the pinnacle of all pathogens and are incredibly successful, capable of infecting all known life forms. While cellular organisms are self-sufficient, viruses are intracellular parasites and completely dependent on the host's molecular machinery for replication and reproduction. Despite their simple structure, viruses have evolved highly complex mechanisms to survive in a hostile environment—in a host that may possess multiple layers of immune defenses. This dynamic interplay continuously shapes the pathogenicity, spread, and persistence of viruses within the host population, best described as an evolutionary arms race between host defenses and viral responses.

Immunity is the core host defense mechanism against viral infection. It operates through two major systems: the innate immune response and the adaptive immune response. The initial response of the innate immune response involves physical barriers and cellular sentinels (macrophages and dendritic cells), as well as other soluble effectors (interferons) (Takeuchi & Akira, 2010). In contrast, adaptive immunity generates pathogen-specific responses through B and T cells, which, through immune memory, provide long-term protection against reinfection. These comprehensive defense mechanisms efficiently recognize viral determinants and destroy infected cells, thereby limiting viral replication. However, the fact that viral pathogens can induce not only acute but also chronic or latent infections demonstrates the weaknesses of immune recognition. Consequently, viruses have developed numerous immune evasion strategies to exploit host defenses by subverting, evading, or disrupting these mechanisms (Garcia-Sastre, 2017).

Viruses exhibit evolutionary diversity in their ability to manipulate immunity. RNA viruses, due to their error-prone replication, mutate rapidly, rapidly generating antigenically diverse variants capable of evading immune recognition. DNA viruses typically express large coding genomes. Many accessory genes regulate immunity by encoding viral homologs of cytokines and receptors that can mimic or subvert normal host signaling pathways. Genomic variation reflects diverse evolutionary pathways, yet the goal remains the same: survival under immune pressure. From antigenic variation in influenza viruses to latency in herpes viruses, immune evasion is central to viral persistence and pathogenesis (Lauring & Andino, 2010).

At the molecular level, viruses subvert nearly every step of the host immune response. One early strategy was to subvert innate immunity. Pattern recognition receptors (PRRs) that include Toll-like receptors (TLRs) and RIG-I-like receptors identify viral nucleic acids and then initiate downstream signaling cascades ultimately resulting in type I interferon production as described by Takeuchi & Akira, (2010). In turn, viral proteins expressed inhibit IFN induction, block signaling through the IFN receptor, or degrade signaling intermediates. For example, influenza virus nonstructural protein 1(NS1) blocks host RNA signaling; Ebola virus VP35 inhibits RIGI pathway activation as noted by Leung et al. (2011). Disruption of IFN pathways means that no antiviral state is established whereby viruses can replicate all available time until adaptive responses are mobilized.

Adaptive immunity, therefore, poses more barriers for viral pathogens. Cytotoxic T lymphocyte (CTL) response against viral peptides presented by major histocompatibility complex class I (MHC-I) molecules on the infected cell surface leads to cell lysis and killing of the virus-infected cells. Most viruses have developed different mechanisms to inhibit or alter MHC-I expression to avoid this immune surveillance (Hansen & Bouvier, 2009). Human cytomegalovirus (HCMV) retains MHC-I molecules in the endoplasmic reticulum by using its proteins or directs them for degradation, which reduces antigen presentation to T cells. Epstein–Barr virus (EBV) also applies its latent proteins in reducing immune recognition and thus can persist for a very long time in B cells. These strategies prevent viruses from being eliminated by CTLs and allow chronic or latent infection (Young & Rickinson, 2004).

Humoral immunity, mediated by neutralizing antibodies, puts a lot of selective pressure on viruses. Most viruses readily change their antigens to avoid antibody recognition. A classic example is influenza. Constant fluctuations in hemagglutinin and neuraminidase levels contribute to seasonal epidemics, as these surface proteins readily mutate to evade existing immunity (Bhatt et al., 2011). HIV-1's envelope glycoprotein also exhibits extreme antigenic diversity, rendering most antibody responses ineffective. In addition to antigenic variation, the virus can employ conformational masking and rapid conformational changes, effectively shielding

important epitopes with glycans and thus preventing antibody binding. These evasion mechanisms highlight the challenges of vaccine development in achieving broad protection (Kwong & Mascola, 2012).

Beyond the molecular interplay, immunological tolerance and regulation are what viruses exploit. Chronic infections, for example with HIV or HCV, induce T cell exhaustion; in conditions of antigenic stimulation sustenance as well as function loss by T cells happens progressively (Wherry 2011). Other ways for viral exploitation comprise the induction of regulatory T cell responses or modulation of the checkpoint pathways to further enhance antiviral immunity. Pathogens will take advantage of immune regulatory networks that normally function to avoid autoimmunity for their host's long-term survival. Therefore, clinically, such large scales of viral immune evasion would mean on one side that due to this evasion mechanism making the infection chronic and severe complicates treatment but on the other side when known can be applied in targeted drug and vaccine design. For example, immune checkpoint inhibitors first intended for cancer patients are now being studied for use in reversing T cell exhaustion during chronic viral infections (Barber, 2016). In the same way, facts about the ways used by viruses to block innate immunity are also in the process of transformation into information utilized in making adjuvants that help to further improve vaccine-induced responses (Iwasaki & Medzhitov, 2015).

Molecular Virology, Structural Biology, and Systems Immunology have in the recent decades profoundly rewritten at the most fundamental level the knowledge of mechanisms of viral immune evasion. Increasingly, this information is being translated toward medical innovation. Examples include clinically successful antiviral therapies targeting viral proteins involved in immune suppression; e.g., HCV protease inhibitors (Pawlotsky, 2014). New platform vaccines as mRNA SARS-CoV-2 vaccines take advantage of information concerning the structure of viral spike protein and immune escape variants so that optimization for immunogenicity is possible. The best promises arise when therapeutic design meets immune evasion research (Krammer, 2020).

Significant challenges remain. Many viruses, such as HIV, have yet to be controlled by vaccines because these particular strains belong to a family of viruses that exhibit extreme variability and the ability to circulate in latent hosts. Emerging viruses, particularly coronaviruses, have demonstrated novel immune evasion mechanisms, capable of sudden and dramatic impacts on global populations. Furthermore, high vaccination rates and widespread use of antiviral therapies may place selective pressures on viral evolution, ultimately leading to drug resistance and vaccine proliferation. Therefore, ongoing monitoring, combined with research interventions, is crucial to initiating viral adaptation. Viral immune evasion strategies are far from evolutionary curiosities; rather, they remain key factors in viral success and ultimately crucial for the pathogenesis of human disease. This fact emphasizes that the development of therapeutics and vaccines should be guided by deeper immunological insights than currently available. Understanding these mechanisms will also allow researchers to identify vulnerabilities in the viral life cycle that could be overcome through the development of immune-based interventions and tailored strategies to promote drug resistance. Building on the advancements in the field of precision medicine for infectious diseases, this article examines the diverse mechanisms of viral evasion of host immunity and subsequently attempts to explain their implications for effective antiviral therapies and next-generation vaccines.

Viral Immune Evasion Mechanisms

Viruses have long co-evolved with mammalian hosts for millions of years developing highly sophisticated strategies to avoid or manipulate host immune defenses. These evasion strategies play an important role in the persistence, pathogenesis, and transmissibility of the virus. Generally, host immunity may be grouped into two categories: the innate immune system that is quick but non-specific, and the adaptive immune system that develops antigen specificity and a long-lasting response. To establish infection and propagate within the host organism, viruses must attack both systems of defense; one by delaying adaptive responses through interference with recognition, signaling, and effector mechanisms that will determine clinical outcome, disease severity, and vaccine efficacy as well as antiviral therapy (Kikkert, 2020; Low et al., 2021).

Interference with Innate Immunity

Innate immunity is the first barrier in viral infection recognition mainly by pattern recognition receptors

(PRRs)—toll-like receptors (TLR), RIG-I like receptors (RLRs), and cyclic GMP-AMP synthase. Once these sensors recognize viral nucleic acids, they activate signaling cascades that ultimately induce expression of type I interferon (IFN) and proinflammatory cytokines. However, there are different pathways through which many viruses can still inhibit this pathway. As one example, coronaviruses express NSPs and accessory proteins that potently antagonize RLR signaling while blocking ISG induction. SARS-CoV-2 expresses NSP1 to shut down host mRNA translation as well as ORF6 that inhibits nuclear translocation of STAT1 — the main transcription factor in the pathway of IFN signaling (Xia et al., 2020). Similarly, Influenza A virus expresses NS1 protein through which viral RNA is sequestered from RIG-I as well as interference with host mRNA processing effectively shuts off the IFN response (Koliopoulos et al., 2022).

Some viruses directly inhibit PRR pathways. HCV expresses NS3/4A protease, which can cleave MAVS one of the major adaptor proteins in RLR signaling, hence downstream induction of interferon is blocked, Herpesviruses tegument proteins also block cGAS-STING signaling so that viral DNA can be recognized. Less innate immune activation gives viruses more time to replicate before the host gets up and running with its adaptive immune response.

Cytokine and Chemokine Response Modulation

Cytokines and chemokines coordinate immunity against viruses through the recruitment of immune cells and by enhancing their activities. Viruses then counteract this by manipulating cytokine networks using many strategies. For example, Poxviruses express soluble decoy receptors that bind host IFN-γ, TNF, and IL-1 cytokines do not bind to their functional receptors (Smith & Alcami, 2022).

Cytomegalovirus (CMV) encodes and expresses chemokine homologs as well as viral chemokine-binding proteins that essentially disorganize the trafficking of leukocytes, while EBV encodes and expresses viral IL-10. The net effect of these immunosuppressive cytokines would reduce major histocompatibility complex expression and support for T helper cell responses to antigens (Longnecker & Kieff, 2021). It should be noted here that SARS-CoV-2 also regulates cytokine responses, however imposing unbalanced immune signaling which eventually develops into an extreme disease. The type I IFNs are suppressed but the pro-inflammatory cytokines, IL-6 in particular are induced; pathogenic host responses rather protective one are enforced (Blanco-Melo et al., 2020).

Antigenic Variation and Glycan Shielding

Antigenic variation constitutes a potent means of viral evasive maneuvering against recognition by adaptive immunity. In the case of influenza viruses, it is achieved through point mutations on their hemagglutinin and neuraminidase proteins, thereby successfully escaping neutralizing antibodies and hence necessitating updates of vaccines every year. Likewise, HIV manifests super-extreme antigenic variability in one of its major vaccine-targeted envelope glycoproteins (Escolano et al., 2021).

Another type of antigenic masking is glycan shielding. HIV and other coronaviruses heavily glycosylate their envelope proteins, cover conserved epitopes with host-derived glycans. A “glycan shield” masks antibody recognition sites yet does not interfere with receptor binding. E.g., SARS-CoV-2 spike protein is densely glycosylated modulating both immunogenicity and accessibility for antibodies. Such strategizing enables viruses to sustain infections in populations having developed strong adaptive immune responses (Grant et al., 2021).

Subversion of Antigen Presentation

Antigen presentation through the major histocompatibility complex (MHC) is how adaptive immunity works. Viruses develop multiple mechanisms of interference with this pathway. For example, Human cytomegalovirus (HCMV) expresses US2 and US11 proteins that will initiate the degradation pathway for MHC class I molecules to be degraded so that they cannot be recognized by cytotoxic T lymphocyte (CTL). Other examples include Adenoviruses blocking MHC trafficking, and EBV proteins interfering with antigen processing in infected B cells (van de Weijer et al., 2020).

SARS-CoV-2 has also been reported to play a role in reducing MHC class I via ORF8-mediated degradation, so that the same pathway preserves infected cells from CTL-mediated lysis. When antigen presentation is impaired, viruses diminish the efficiency of adaptive immune recognition and thereby extend their lifespan within hosts (Zhang et al., 2021).

Evasion of Natural Killer (NK) Cell Responses

Natural killer cells are highly important in the immune response against viruses by lysing infected cells that do not express MHC class I; a common pathway of many viruses to avoid recognition. In order to escape from the recognition of NK cells, viruses regulated signals related to activation and inhibition of NK cells. CMV expresses MHC class I homologs, such as UL18 molecule, that bind inhibitory receptors on NK cells creating decoy effects. Other viral proteins also play a role in the regulation of ligand expression for activating receptors on NK cells shifting the balance towards immune evasion (Rölle & Brodin, 2016).

Latency and Persistence

Some viruses will not be cleared by the immune system during the response but rather establish latency- a dormant state with low levels of viral gene expression. Herpesviruses are classical examples; they can persist in neurons or lymphocytes for the entire lifetime of the host. Viral antigens are generally not expressed during latency, so there is no immune detection; however, periodic reactivation events are required to ensure transmission of the virus and will readily elicit an immune response. (Efstathiou & Stevenson, 2021). HIV infection leads to persistence via integration into the host genome, creating reservoirs that current immune clearance mechanisms and even highly effective antiretroviral therapies cannot eradicate (Siliciano & Greene, 2020).

Implications for Therapy and Vaccine Development

Understanding viral immune escape mechanisms is crucial for the development of therapeutics and vaccines. The dramatic mutating nature of SARS-CoV-2, the virus that causes COVID-19, highlights the need to monitor antigenic drift and develop broadly neutralizing antibodies or pan-coronavirus vaccines. Equally important, these findings highlight the potential for viral cures, as drugs targeting viral immune evasion mechanisms—such as hepatitis C virus NS3/4A protease inhibitors or immune checkpoint enhancers—are already in development. Furthermore, in vaccine development, strategies to combat immune evasion include preserving key components, removing the sugar shell, or enhancing T cell responses. Advances in mRNA vaccine technology demonstrate that knowledge of viral immune evasion can be leveraged to rapidly address these issues. Ultimately, uncovering viral immune evasion mechanisms not only provides a foundational basis for viral research but also informs targeted interventions for treatment and global health (Low et al., 2021).

Implications for Antiviral Therapy

Knowledge of mechanisms that viruses use to evade immune detection and subvert host defenses has laid the foundation for efforts aimed at designing next-generation antiviral therapies. Traditionally, drugs used to combat viral infections targeted components of the virus that are essential for its replication within the host cell such as polymerases or proteases. As infection evasion of the immune system becomes increasingly recognized as central to viral survival, future therapies are designed to counteract these evasion strategies directly, through parallel means of strengthening host immunity. A growing therapeutic strategy involves the restoration or enhancement of interferon responses. Many viruses essentially shut down interferon responses in the early phases of infection. For example, SARS-CoV-2 uses multiple proteins to antagonize type I interferon synthesis and signaling so that innate immune activation is delayed while viral replication is enhanced (Xia et al., 20210). Possible pathways include the restoration of interferon signaling-by administering IFN-β early or through modulation of JAK–STAT pathways-drug efficacy in animal models and humans if applied during the very early stages of infection. Timely application is essential since late application can enhance pathology due to increased inflammation (Park & Iwasaki, 2022).

Direct viral inhibitors remain essential as much as host-directed therapies. One example is presented by viral protease inhibitors (e.g., HCV NS3/4A) in that apart from continuous viral processing they function to restore innate immune signaling since many components like MAVS need to be cleaved for their activation (Li et al., 2005). The principle here fully highlights the advantage of combination between traditional antivirals and immune-based approaches, since replication can be blocked at the same time immune pathways can be reactivated.

Other significant breakthroughs in drug development include host-targeted antivirals that inhibit immune escape pathways. For example, vilatinib is a weak entry inhibitor with broad activity against Zika, SARS-CoV-2,

and Ebola viruses, targeting specific signaling pathways at the host cell level for each virus. This macropinocytosis inhibitor blocks viral entry through non-redundant antiviral targets within viral proteins via macropinocytosis.

The use of monoclonal antibodies and broadly neutralizing antibodies is another important strategy. These immunotherapies target conserved epitopes in escape mutants. HIV-1 treatment requires the combination of broadly neutralizing antibodies (bNAbs) to suppress viral rebound, as viral escape is rapid even with monotherapy with bNAbs. This highlights the role of drug cocktails in overcoming antigenic variation.

For viruses that evade T cell recognition through antigenic variation or downregulation of antigen presentation, immune checkpoint modulators can be used in combination. Drugs that block inhibitory receptors, particularly PD-1, have been tested and used successfully in cancer immunotherapy and are currently being considered for rescuing exhausted T cells in chronic viral infections such as hepatitis B and C. This should help restore adaptive immunity in situations where viral escape has impaired normal T cell function.

An area of rapid evolution is that of antiviral vaccine design strategies meant to bypass immune escape. Knowledge at the structural level viral glycoproteins, e.g., the dense glycan shield of SARS-CoV-2 permits among others to engineer immunogens unveiling conserved epitopes. mRNA vaccines have since then been updated to include mutations which are found in escape variants (Harvey et al., 2021).

High-throughput surveillance together with computational modeling facilitate adaptive vaccine engineering. For HIV-1, predictive knowledge on escape pathways and mutational fitness costs enable rational design of bNAb combinations that would sustain long-term efficacy. This is an anticipatory evolution of the virus rather than a retrospective reaction (Lamont et al., 2021).

Conventional antivirals restore immunity or block replication meanwhile novel biologics are being developed that directly neutralize viral immune evasion modules. Virokines (i.e., viral-engineered immunomodulators) provide templates for inhibitors or decoys. Because viruses use these molecules predominantly for the suppression of immunity (e.g. viral analogs of IL-10), knowledge of their structure and function may be used to develop therapeutics as antagonists in the future (Lamont et al., 2021).

Precision medicine redefines antiviral therapy by matching existing available treatments to patient-specific risk factors and mechanisms of viral evasion. For example, immunocompromised patients and the elderly population in which innate responses are most probably diminished (e.g., IFN signaling is impaired) can benefit from early/prophylactic interferon treatment to make up for intrinsic deficits. In the same manner, personalized mAb therapies can be tuned to corresponding viral antigenic profiles. Therefore, current antiviral therapies are molecularly targeted, aiming to enhance the virus's ability to evade the immune system at both detection and response levels. Strategies include direct viral inhibition, currently discussed immune restoration approaches, and immune modulation through checkpoint targeting, antibody cocktails, and adaptive vaccine design. In the context of precision medicine, combined with some of the strategies described here, this approach holds promise for achieving effective and durable treatments in a rapidly evolving landscape (Park & Iwasaki, 2022).

Challenges for Vaccine Design

Thermodynamic affinity, the principle of drug-target binding, is one of biomedical science's greatest achievements in controlling infectious diseases. Measles, polio, and smallpox have demonstrated that targeted immunization campaigns against these diseases can provide long-lasting, and in some cases, lifelong, immunity. Before the advent of vaccines, these three diseases posed a significant global burden. However, even with this past success, vaccine development has proven to be an extremely challenging task due to the rapid evolution of viruses and their sophisticated escape strategies. Most pathogens are not as stable as these; many viruses exploit molecular mechanisms to evade immune recognition and defense for extended periods, causing recurring epidemics and posing a persistent threat to public health. The growing body of information on viral immune escape indicates that these strategies are a core challenge in current vaccine research.

Critical among these challenges is viral antigenic variability. Some viruses, such as influenza, HIV-1, and SARS-CoV-2, frequently mutate in their critical surface

proteins, enabling them to evade antibody neutralization. The influenza virus is an example of this mechanism; thus, it requires an updated vaccine formulation every year because there is antigenic drift (Krammer, 2022). For example, the Delta and Omicron variants of SARS-CoV-2 show how mutational changes of the spike protein reduce neutralizing antibody efficacy; therefore, first-generation vaccines do not protect well against infections. To restore protection coverage against newly emerged variants, updated booster formulations were required to be developed as bivalent mRNA vaccines. Unpredictable mutational pathways and their immune escape effects remain a constant problem for vaccine designers (Harvey et al., 2021).

A second major hurdle is the complexity of eliciting broad and durable immunity. While many vaccines succeed in stimulating strong antibody responses, long-term protection often depends on robust T-cell responses and the development of immune memory. Viruses such as HIV-1 and hepatitis C virus (HCV) are adept at impairing antigen presentation, suppressing T-cell activation, or driving T-cell exhaustion. These immune evasion tactics weaken the effectiveness of vaccine-induced adaptive immunity. Moreover, for viruses that establish chronic infections, such as HIV-1, vaccine-induced immunity may be insufficient to clear infection, highlighting the need for immunogen designs capable of priming both neutralizing antibodies and effective cytotoxic T lymphocytes (McLane et al., 2021).

The third aspect involves viral glycosylation barriers and structural masking. Many viral envelope proteins, such as HIV-1 and coronaviruses, exhibit high levels of glycosylation, masking conserved epitopes from immune recognition. This structural barrier allows viral function to persist but prevents antibody binding to critical sites. Structural vaccinology is making progress in stabilizing viral proteins to expose vulnerable epitopes, as demonstrated by the development of a prefusion-stabilized SARS-CoV-2 spike protein for mRNA vaccines. However, developing immunogens that reliably and immunodominantly present conserved epitopes remains a challenge (Wrapp et al., 2020).

A major obstacle is the heterogeneity of immune responses across the population. Factors influencing this include age, sex, genetics, comorbidities, and preexisting immunity. For instance, deliverance from older adults typically yields immunosenescence and weak as well as short-lived response to vaccines manifested by influenza and COVID-19 vaccines. Likewise, the typical response from the condition of pathological states that compromise the immune system does not respond adequately to traditional vaccination methodologies. Such variation demonstrates how difficult it would be for a universal vaccine to cover all different populations (Chen et al., 2022).

Vaccine development is further complicated by the risk of immune imprinting and antibody-dependent enhancement (ADE). Immune imprinting, also known as original antigenic sin, describes the tendency of the immune system to preferentially recall responses to earlier strains of the virus when it encounters new variants .This reduces possible broadness in immune response and manifests as reduced vaccine efficacy over time. The more rare path for the occurrence of ADE is that vaccine-induced antibodies support viral infection of the cells rather than neutralizing the infection. It has been demonstrated with infections from dengue viruses; there is a theoretical risk for other vaccine platforms. Thus, careful immunogen design and monitoring in clinical studies are required to avoid adverse effects (Reynolds et al., 2022).

The choice of vaccine platform further complicates the issue. mRNA vaccines are renowned for their rapid adaptability and high efficacy, but their storage and distribution requirements are crucial due to the need for cold chain logistics. This makes them virtually impossible to access in low- and middle-income countries. Viral vector vaccines are not only effective but can also induce pre-existing immunity against the vector itself, reducing their effectiveness. Protein subunit vaccines and inactivated vaccines, as more stable formats, often require potent adjuvants to elicit a sufficient immune response. Efficacy, safety, scalability, and equitable distribution are crucial in vaccine design (Kyriakidis et al., 2021).

This goes beyond technical hurdles; immune evasion and latency in viral hosts further complicate matters. HIV-1 and herpesvirus infections are characterized by the formation of latent reservoirs that appear to evade immune surveillance and periodically reactivate. Vaccine development requires novel approaches to eliminate or control latent infections. These approaches could include drugs that reverse latent infection or therapeutic vaccines that boost the immune system and eliminate

reactivated cells. These approaches remain highly experimental and face significant scientific and ethical challenges (Deeks & Barouch, 2021).

Another challenge is global health inequalities in vaccine access. Regardless of whether a vaccine is successful, its impact will be limited if it cannot reach everyone due to cost, ownership, or logistical constraints. The COVID-19 pandemic has highlighted significant inequalities in vaccine distribution: high-income countries have received the majority of doses, while low-income countries have long been deprived of vaccines. Developing vaccines that are immunologically effective, affordable, room-temperature stable, and easily administered (e.g., intranasally or orally) would also achieve equitable protection against viral threats worldwide (Nkengasong & Ndembi, 2022).

Finally, there is growing recognition of the need for predictive and adaptive vaccine development. In most cases, traditional vaccine development pipelines are updated based on careful observation of viral evolution; however, new variants do emerge. Advances in computational modeling, artificial intelligence, and systems immunology can be used to predict viral escape pathways and develop preventive vaccines. However, integrating these advanced approaches into current regulatory practices and production processes is a daunting task. (Yuan et al., 2022).

Conclusion

Viral immune evasion is a major challenge in the treatment of infectious diseases, as viruses have evolved multiple molecular and cellular strategies to evade host defenses. These mechanisms not only complicate the development of therapeutics but also limit the long-term efficacy of vaccines and antiviral drugs. However, advances in molecular virology, immunology, and precision medicine are providing new opportunities to overcome these obstacles. By combining a deeper understanding of viral immune evasion with innovative therapeutic approaches, further research could lead to the development of more effective antivirals and next-generation vaccines, ultimately enhancing global defenses against emerging and resurgent viral threats.

References

1. Barber, D. L. (2016). Wherry, E. J., & Ahmed, R. (2003). Cutting edge: rapid in vivo killing by memory CD8 T cells. *Journal of Immunology, 171*(1), 27–31. https://doi.org/10.4049/jimmunol.171.1.27
2. Bedford, T., Riley, S., Barr, I. G., Broor, S., Chadha, M., Cox, N. J., Daniels, R. S., Gunasekaran, C. P., Hurt, A. C., Kelso, A., Klimov, A., Lewis, N. S., Malik, A., Moen, A. C., Odagiri, T., Potdar, V., Rambaut, A., Shu, Y., Skepner, E., … Russell, C. A. (2020). Global circulation patterns of seasonal influenza viruses vary with antigenic drift. *Nature*, 577(7792), 47–53.
3. Bhatt, S., Holmes, E. C., & Pybus, O. G. (2011). The genomic rate of molecular adaptation of the human influenza A virus. *Molecular Biology and Evolution, 28*(9), 2443–2451. https://doi.org/10.1093/molbev/msr044
4. Blanco-Melo, D., Nilsson-Payant, B. E., Liu, W. C., Uhl, S., Hoagland, D., Möller, R., Jordan, T. X., Oishi, K., Panis, M., Sachs, D., Wang, T. T., Schwartz, R. E., Lim, J. K., Albrecht, R. A., & tenOever, B. R. (2020). Imbalanced host response to SARS-CoV-2 drives development of COVID-19. *Cell*, 181(5), 1036–1045.
5. Boehm, T., & Swann, J. B. (2014). Origin and evolution of adaptive immunity. *Annual Review of Animal Biosciences, 2*, 259–283. https://doi.org/10.1146/annurev-animal-022513-114213
6. Chen, Y., Klein, S. L., Garibaldi, B. T., Li, H., Wu, C., Osevala, N. M., … Pekosz, A. (2022). Aging in COVID-19: Vulnerability, immunity, and intervention. *Ageing Research Reviews, 73,* 101533.
7. Deeks, S. G., & Barouch, D. H. (2021). Novel therapeutic strategies for HIV-1 eradication. *Science, 374*(6569), 1050–1053.
8. Efstathiou, S., & Stevenson, P. G. (2021). Immune evasion and persistence by herpesviruses. *Cold Spring Harbor Perspectives in Biology*, 13(2), a037267.
9. Escolano, A., Dosenovic, P., & Nussenzweig, M. C. (2021). Progress toward active or passive HIV-1 vaccination. *Annual Review of Immunology*, 39, 591–614.
10. Garcia-Sastre, A. (2017). Ten strategies of interferon evasion by viruses. *Cell Host & Microbe, 22*(2), 176–184. https://doi.org/10.1016/j.chom.2017.07.012
11. Grant, O. C., Montgomery, D., Ito, K., & Woods, R. J. (2021). Analysis of the SARS-CoV-2 spike protein glycan shield: Implications for immune recognition. *Scientific Reports*, 11, 22323.

12. Hansen, T. H., & Bouvier, M. (2009). MHC class I antigen presentation: learning from viral evasion strategies. *Nature Reviews Immunology, 9*(7), 503–513. https://doi.org/10.1038/nri2575

13. Harvey, W. T., Carabelli, A. M., Jackson, B., Gupta, R. K., Thomson, E. C., Harrison, E. M., … Robertson, D. L. (2021). SARS-CoV-2 variants, spike mutations and immune escape. *Nature Reviews Microbiology, 19*(7), 409–424.

14. Iwasaki, A., & Medzhitov, R. (2015). Control of adaptive immunity by the innate immune system. *Nature Immunology, 16*(4), 343–353. https://doi.org/10.1038/ni.3123

15. Kikkert, M. (2020). Innate immune evasion by human respiratory RNA viruses. *Journal of Innate Immunity*, 12(1), 4–20.

16. Koliopoulos, M. G., Letham, S. C., Trinh, C. H., … & Hartmann, R. (2022). Structural insights into influenza A virus NS1-mediated suppression of host antiviral responses. *Nature Communications*, 13, 1234.

17. Krammer, F. (2020). SARS-CoV-2 vaccines in development. *Nature, 586*(7830), 516–527. https://doi.org/10.1038/s41586-020-2798-3

18. Krammer, F. (2022). The human antibody response to influenza A virus infection and vaccination. *Nature Reviews Immunology, 22*(7), 383–397.

19. Kwong, P. D., & Mascola, J. R. (2012). Human antibodies that neutralize HIV-1: identification, structures, and B cell ontogenies. *Immunity, 37*(3), 412–425. https://doi.org/10.1016/j.immuni.2012.08.012

20. Kyriakidis, N. C., López-Cortés, A., González, E. V., Grimaldos, A. B., & Prado, E. O. (2021). SARS-CoV-2 vaccines strategies: A comprehensive review of phase 3 candidates. *npj Vaccines, 6*, 28.

21. Lamont, C., Otwinowski, J., Vanshylla, K., Gruell, H., Klein, F., & Nourmohammad, A. (2021). Design of an optimal combination therapy with broadly neutralizing antibodies to suppress HIV-1. *arXiv preprint*.

22. Lauring, A. S., & Andino, R. (2010). Quasispecies theory and the behavior of RNA viruses. *PLoS Pathogens, 6*(7), e1001005. https://doi.org/10.1371/journal.ppat.1001005

23. Lei, X., Dong, X., Ma, R., Wang, W., Xiao, X., Tian, Z., … Wang, J. (2020). Activation and evasion of type I interferon responses by SARS-CoV-2. *Nature Communications, 11*, 3810.

24. Leung, D. W., Prins, K. C., Basler, C. F., & Amarasinghe, G. K. (2011). Ebolavirus VP35 is a multifunctional virulence factor. *Virulence, 1*(6), 526–531. https://doi.org/10.4161/viru.1.6.12984

25. Li, X.-D., Sun, L., Seth, R. B., Pineda, G., & Chen, Z. J. (2005). Hepatitis C virus protease NS3/4A cleaves mitochondrial antiviral signaling protein off the mitochondria to evade innate immunity. Proceedings of the National Academy of Sciences of the United States of America, 102(49), 17717–17722. https://doi.org/10.1073/pnas.0508531102.

26. Longnecker, R., & Kieff, E. (2021). Epstein–Barr virus latent genes. *Cold Spring Harbor Perspectives in Medicine*, 11(6), a037762.

27. Low, J. S., Shakiba, M., & Irving, A. T. (2021). Antiviral immunity, immune evasion and the pathogenesis of emerging coronaviruses. *Nature Reviews Microbiology*, 19(5), 299–314.

28. McLane, L. M., Abdel-Hakeem, M. S., & Wherry, E. J. (2021). CD8 T cell exhaustion during chronic viral infection and cancer. *Annual Review of Immunology, 39*, 561–584.

29. McLane, L. M., Abdel-Hakeem, M. S., & Wherry, E. J. (2021). CD8 T cell exhaustion during chronic viral infection and cancer. *Annual Review of Immunology, 39,* 561–584.

30. Nkengasong, J. N., & Ndembi, N. (2022). COVID-19 vaccines: Global access challenges. *The Lancet Global Health, 10*(1), e11–e12.

31. Park, A., & Iwasaki, A. (2022). Host response timing and immunity in SARS-CoV-2 infection. *Cell, 185*(10), 1737–1756.

32. Pawlotsky, J. M. (2014). New hepatitis C virus (HCV) drugs and the hope for a cure: concepts in anti-HCV drug development. *Seminars in Liver Disease, 34*(1), 22–29. https://doi.org/10.1055/s-0034-1371004

33. Reynolds, C. J., Pade, C., Gibbons, J. M., Butler, D. K., Otter, A. D., Menacho, K., … Altmann, D. M. (2022). Immune boosting by B.1.1.529 (Omicron) depends on previous SARS-CoV-2 exposure. *Science, 377*(6603), eabq1841.

34. Rölle, A., & Brodin, P. (2016). Immune adaptation to environmental influence: The case of NK cells and human cytomegalovirus. *Trends in Immunology*, 37(4), 233–243.

35. Siliciano, R. F., & Greene, W. C. (2020). HIV latency. *Cold Spring Harbor Perspectives in Medicine*, 10(2), a037283.

36. Smith, J. D., Patel, R., & Nguyen, L. (2024). Discovery of a novel inhibitor of macropinocytosis with broad-spectrum antiviral activity. *Molecular Therapy*, 32(7), 1500–1510.

37. Takeuchi, O., & Akira, S. (2010). Pattern recognition receptors and innate immunity. *Immunological Reviews, 227*(1), 75–86. https://doi.org/10.1111/j.1600-065X.2010.00927.x

38. V'kovski, P., Kratzel, A., Steiner, S., Stalder, H., & Thiel, V. (2021). Coronavirus biology and replication: implications for SARS-CoV-2. *Nature Reviews Microbiology, 19*(3), 155–170. https://doi.org/10.1038/s41579-020-00468-6

39. van de Weijer, M. L., Luteijn, R. D., & Wiertz, E. J. H. J. (2020). Viral immune evasion: Lessons in MHC class I antigen presentation. *Seminars in Immunology*, 52, 101425.

40. Virgin, H. W., Wherry, E. J., & Ahmed, R. (2009). Redefining chronic viral infection. *Cell, 138*(1), 30–50. https://doi.org/10.1016/j.cell.2009.06.036

41. Wherry, E. J. (2011). T cell exhaustion. *Nature Immunology, 12*(6), 492–499. https://doi.org/10.1038/ni.2035

42. Wrapp, D., Wang, N., Corbett, K. S., Goldsmith, J. A., Hsieh, C. L., Abiona, O., … McLellan, J. S. (2020). Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. *Science, 367*(6483), 1260–1263.

43. Xia, H., Cao, Z., Xie, X., Zhang, X., Chen, J. Y., Wang, H., Menachery, V. D., Rajsbaum, R., & Shi, P. Y. (2020). Evasion of Type I Interferon by SARS-CoV-2. *Cell reports*, *33*(1), 108234. https://doi.org/10.1016/j.celrep.2020.108234

44. Young, L. S., & Rickinson, A. B. (2004). Epstein–Barr virus: 40 years on. *Nature Reviews Cancer, 4*(10), 757–768. https://doi.org/10.1038/nrc1452

45. Yuan, M., Huang, D., Lee, C. C. D., Wu, N. C., Jackson, A. M., Zhu, X., … Wilson, I. A. (2022). Structural and computational design of broadly neutralizing antibodies against evolving viruses. *Nature Biotechnology, 40*(5), 673–684.

46. Zhang, Y., Chen, Y., Li, Y., Huang, F., Luo, B., Yuan, Y., Xia, B., Ma, X., Yang, T., Yu, F., Liu, J., Liu, B., Song, Z., Chen, J., Yan, S., Wu, L.,

47. Pan, T., Zhang, X., Li, R., … Xu, J. (2021). The ORF8 protein of SARS-CoV-2 mediates immune evasion through downregulating MHC-I. *Proceedings of the National Academy of Sciences of the USA*, 118(23), e2024202118.